Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 186)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
2 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
3 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
4 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
5 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 4 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
6 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
7 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
8 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
9 |
|
Azithromycin |
Approved |
Phase 4 |
|
83905-01-5 |
447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
Azadose
AZASITE
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
AZITHROMYCIN
AZITHROMYCIN ANHYDROUS
Azithromycin dihydrate
AZITHROMYCIN HYDRATE
Azithromycin monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromicina
Azitromin
AZYTER
Azythromycin
Bayer brand OF azithromycin dihydrate
CLAMELLE
CP 62993
|
CP-62,993
CP-62993
Dihydrate, azithromycin
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
Lesvi brand OF azithromycin dihydrate
Mack brand OF azithromycin dihydrate
Monohydrate, azithromycin
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
Sumamed
SUNAMED
Toraseptol
Ultreon
Vinzam
Vita brand OF azithromycin dihydrate
XZ 405
XZ 450
XZ-450
Zentavion
Zithromax
Zitromax
Zmax
|
|
10 |
|
Salbutamol |
Approved, Vet_approved |
Phase 4 |
|
18559-94-9 |
2083 |
Synonyms:
(±)-SALBUTAMOL
(L)-Albuterol
1-(Tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol
2-(Tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol
2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol
ACCUNEB
Aerolin
AEROLIN 400
AEROLIN AUTO
AIROMIR
AIRSALB
Albuterol
Albuterol sulfate
Albuterol Sulphate
albuterol|SCH-13949W|Ventolin®
Almotex
Alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
Alti-salbutamol
Anebron
Arubendol-salbutamol
Asmadil
Asmanil
Asmasal
ASMASAL CLICKHALER
ASMASAL SPACEHALER
Asmatol
Asmaven
ASMAVENT
Asmidon
Asmol
Asmol uni-dose
Asthalin
Asthavent
Broncho-spray
Broncovaleas
Bronter
BTA204
Bugonol
Bumol
Butamol
Buto-asma
Butohaler
Butotal
Butovent
Buventol
Cetsim
Cobutolin
COMBIVENT
COMBIVENT UDVS
Dilatamol
DL-Albuterol
DL-N-Tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine
DL-Salbutamol
DUONEB
Ecovent
Farcolin
Gerivent
Grafalin
IPRAMOL STERI-NEB
KENTAMOL
Levalbuterol
LIBETIST
Libretin
Loftan
MAXIVENT
Medolin
Mozal
Novosalmol
Parasma
Pneumolat
ProAir
PROAIR HFA
Proventil
|
Proventil hfa
Proventil inhaler
PROVENTIL-HFA
Respax
Respolin
RIMASAL
Rotahaler
R-Salbutamol
Sabutal
Salamol
SALAMOL E-BREATHE
SALAPIN
Salbetol
Salbron
Salbu-basf
Salbu-fatol
Salbuhexal
Salbulin
SALBULIN NOVOLIZER
Salbupur
Salbusian
Salbutalan
SALBUTAMOL
Salbutamol free base
Salbutamol sulfate
Salbutamol sulphate
Salbutamolum
Salbutan
Salbutard
Salbutine
Salbutol
Salbuven
Salbuvent
SALIPRANEB
Sallbupp
Salmaplon
Salomol
Salvent
Saventol
SCH 13949W
SCH-13949W
Servitamol
Solbutamol
Spreor
STERI-NEB SALAMOL
Sultanol
Sultanol N
Suprasma
Suxar
Theosal
Tobybron
Vencronyl
Venetlin
Ventalin Inhaler
Ventamol
Ventilan
Ventiloboi
VENTMAX SR
Ventodisks
Ventolin
VENTOLIN CR
VENTOLIN E-BREATHE
VENTOLIN HFA
Ventolin inhaler
Ventolin rotacaps
Ventoline
Volare albuterol hfa
Volare easi-breathe
Volma
Volmax
Xopenex
Xopenex HFA
Zaperin
|
|
11 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
5281004 40000 63006 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11Β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
AIRCORT
Bidien
BUDEFLAM AQUANASE
BUDELIN NOVOLIZER
BUDENOFALK
Budeson
Budesónida
BUDESONIDE
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budicort
CORTIMENT
Cortivent
Desowen
DEXBUDESONIDE
DUORESP SPIROMAX
ENTOCORT
ENTOCORT CR
Entocort ec
Entocort®|Eohilia® (budesonide oral suspension)|Jorveza®|Pulmicort®|S-1320|Uceris®
Horacort
MAP0010
|
MAP-0010
Micronyl
Noex
ORTIKOS
PREFERID
PULMAXAN
Pulmicort
PULMICORT FLEXHALER
PULMICORT L.S.
Pulmicort Nebuamp
PULMICORT RESPULES
Pulmicort Turbuhaler
R01AD05
Rhinocort
RHINOCORT ALLERGY
RHINOCORT AQUA
RHINOCORT AQUA 64
Rhinocort Turbuhaler
Rhinosol
S-1320
Spirocort
SYMBICORT
Tridesilon
Uceris
|
|
12 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
13 |
|
Protective Agents |
|
Phase 4 |
|
|
|
14 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
15 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
16 |
|
Antiemetics |
|
Phase 4 |
|
|
|
17 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
18 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
19 |
|
Methylprednisolone Acetate |
|
Phase 4 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
20 |
|
Hormones |
|
Phase 4 |
|
|
|
21 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
22 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
23 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
24 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
25 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
26 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
27 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
29 |
|
Tocolytic Agents |
|
Phase 4 |
|
|
|
30 |
|
Budesonide, Formoterol Fumarate Drug Combination |
|
Phase 4 |
|
|
|
31 |
|
Formoterol Fumarate |
|
Phase 4 |
|
|
|
32 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
33 |
|
Asparaginase Escherichia coli |
Approved, Investigational |
Phase 3 |
|
9015-68-3 |
|
Synonyms:
ASPARAGINASE
Asparaginase (E. coli)
COLASPASE
CRASNITIN
ELSPAR
|
Escherichia coli L-asparaginase
L-ASPARAGINASE
L-asparagine amidohydrolase
NSC-109229
Putative L-asparaginase precursor
|
|
34 |
|
Tioguanine |
Approved |
Phase 3 |
|
154-42-7 |
2723601 |
Synonyms:
2 Amino 6 purinethiol
2-Amino 6MP
2-Amino-1,7-dihydro-6H-purine-6-thione
2-Amino-1,9-dihydropurine-6-thione
2-Amino-6-mercaptopurine
2-Amino-6-merkaptopurin
2-Amino-6-purinethiol
2-Aminopurin-6-thiol
2-Aminopurine-6(1H)-thione
2-Aminopurine-6-thiol
6 Thioguanine
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-mercaptoguanine|6-thioguanine|Lanvis®|Tabloid®
6-TG
6-Thioguanine
Anhydrous, thioguanine
Glaxo wellcome brand OF thioguanine
Glaxo wellcome brand OF tioguanine
GlaxoSmithKline brand OF thioguanine
GlaxoSmithKline brand OF tioguanine
Lanvis
NSC-752
|
NSC-76504
Tabloid
TG
ThG
Thioguanin GSK
Thioguanine
Thioguanine anhydrous
Thioguanine hemihydrate
Thioguanine monosodium salt
Thioguanine tabloid
Thioguanine, anhydrous
ThioguaninGSK
Thioguanin-GSK
Tioguanin
Tioguanina
Tioguanina wellcome
TIOGUANINE
Tioguanine glaxosmithkline brand
TIOGUANINE HEMIHYDRATE
Tioguaninum
Wellcome brand OF thioguanine
Wellcome U3B
|
|
35 |
|
Daunorubicin |
Approved |
Phase 3 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
36 |
|
Busulfan |
Approved, Investigational |
Phase 3 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
37 |
|
Aldesleukin |
Approved |
Phase 3 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
38 |
|
Benralizumab |
Approved, Investigational |
Phase 3 |
|
1044511-01-4 |
|
Synonyms:
BENRALIZUMAB
BIW-8405
BIW-8405|Fasenra®|KHK4563|MEDI-563
|
|
|
39 |
|
Ketotifen |
Approved |
Phase 3 |
|
34580-14-8, 34580-13-7 |
3827 |
Synonyms:
(R)-KETOTIFEN
10-(1-Methyl-4-piperidinylidene)-5H-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one
Alaway
Fumarate, ketotifen
HC-20511
HC-20511 FUMARATE
HC-20511|Zaditor®
KETOTIFEN
Ketotifen fumarate
|
Ketotifene
Ketotifene fumarate
Ketotifeno
Ketotifenum
Ketotiphen
Ketotiphene
ZAD511
Zaditen
ZADITOR
|
|
40 |
|
Histamine |
Approved, Investigational |
Phase 3 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
41 |
|
Reslizumab |
Approved, Investigational |
Phase 3 |
|
241473-69-8 |
|
Synonyms:
CEP-38072
CINQAERO
CINQAIR
CINQUIL
DCP 835
|
DCP-835
Reslizumab
SCH 55700
SCH55700
SCH-55700
|
|
42 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
43 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
44 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
45 |
|
N-Methylaspartate |
|
Phase 3 |
|
|
|
46 |
|
Anti-Retroviral Agents |
|
Phase 3 |
|
|
|
47 |
|
Interleukin-2 |
|
Phase 3 |
|
|
|
48 |
|
Anti-HIV Agents |
|
Phase 3 |
|
|
|
49 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
50 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 207)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma. |
Unknown status |
NCT04585997 |
Phase 4 |
Mepolizumab;Omalizumab |
2 |
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil |
Unknown status |
NCT04228588 |
Phase 4 |
Mepolizumab 100 MG [Nucala] |
3 |
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma |
Unknown status |
NCT03652376 |
Phase 4 |
Benralizumab |
4 |
Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes |
Completed |
NCT01524536 |
Phase 4 |
prednisone |
5 |
Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia |
Completed |
NCT00632554 |
Phase 4 |
prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months |
6 |
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) |
Completed |
NCT02654145 |
Phase 4 |
Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab |
7 |
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy |
Recruiting |
NCT04710134 |
Phase 4 |
|
8 |
BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters |
Recruiting |
NCT05552508 |
Phase 4 |
|
9 |
A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM) |
Recruiting |
NCT04276233 |
Phase 4 |
Prednisone/ Prednisolone;Salbutamol |
10 |
Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial |
Recruiting |
NCT04319705 |
Phase 4 |
Azithromycin;Placebo oral tablet |
11 |
Predictive Signature of Benralizumab Response |
Recruiting |
NCT04565483 |
Phase 4 |
Benralizumab Prefilled Syringe |
12 |
SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab |
Active, not recruiting |
NCT04159519 |
Phase 4 |
Symbicort®;Fasenra®;Ventolin® |
13 |
Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma |
Completed |
NCT02559791 |
Phase 2, Phase 3 |
Placebo |
14 |
A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome |
Completed |
NCT00465985 |
Phase 3 |
ACZ885;Placebo |
15 |
An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma |
Completed |
NCT04305405 |
Phase 3 |
Benralizumab |
16 |
A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) |
Completed |
NCT02555371 |
Phase 3 |
Placebo |
17 |
An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease |
Completed |
NCT00685373 |
Phase 3 |
Canakinumab (ACZ885) |
18 |
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control |
Completed |
NCT02281318 |
Phase 3 |
Placebo;SOC |
19 |
An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan |
Completed |
NCT00991146 |
Phase 3 |
canakinumab |
20 |
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma |
Completed |
NCT01270464 |
Phase 3 |
Reslizumab;Placebo |
21 |
An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01576367 |
Phase 3 |
|
22 |
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma |
Completed |
NCT01287039 |
Phase 3 |
Reslizumab;Placebo |
23 |
A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis |
Completed |
NCT03473977 |
Phase 2, Phase 3 |
|
24 |
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma |
Completed |
NCT01285323 |
Phase 3 |
Reslizumab;Placebo |
25 |
A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma |
Completed |
NCT01508936 |
Phase 3 |
Reslizumab;Placebo |
26 |
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01302860 |
Phase 3 |
ACZ885 |
27 |
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622 |
Completed |
NCT03306043 |
Phase 3 |
Mepolizumab |
28 |
Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome |
Completed |
NCT02836496 |
Phase 3 |
Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules |
29 |
A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES |
Completed |
NCT00086658 |
Phase 3 |
mepolizumab |
30 |
INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation |
Completed |
NCT00799461 |
Phase 3 |
|
31 |
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years |
Completed |
NCT00369317 |
Phase 3 |
asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide |
32 |
Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years |
Completed |
NCT00006363 |
Phase 3 |
cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan |
33 |
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation |
Completed |
NCT01305200 |
Phase 3 |
supersaturated calcium phosphate rinse |
34 |
A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD |
Recruiting |
NCT04075331 |
Phase 2, Phase 3 |
Mepolizumab;Placebo |
35 |
Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia |
Recruiting |
NCT02484248 |
Phase 3 |
Ketotifen;Placebo |
36 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis |
Recruiting |
NCT05214768 |
Phase 3 |
CC-93538;Placebo |
37 |
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) |
Recruiting |
NCT05251909 |
Phase 3 |
|
38 |
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis |
Recruiting |
NCT05152563 |
Phase 3 |
AK002 |
39 |
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies |
Recruiting |
NCT03470311 |
Phase 3 |
|
40 |
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) |
Recruiting |
NCT04191304 |
Phase 3 |
|
41 |
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES) |
Recruiting |
NCT05334368 |
Phase 3 |
Depemokimab |
42 |
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome |
Recruiting |
NCT04965636 |
Phase 3 |
Mepolizumab |
43 |
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES) |
Active, not recruiting |
NCT02130882 |
Phase 2, Phase 3 |
benralizumab |
44 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
Active, not recruiting |
NCT04322604 |
Phase 3 |
lirentelimab (AK002) |
45 |
A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
Enrolling by invitation |
NCT04620811 |
Phase 3 |
lirentelimab |
46 |
Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline® |
Terminated |
NCT00505648 |
Phase 3 |
Tegeline® |
47 |
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma |
Terminated |
NCT03052725 |
Phase 3 |
reslizumab |
48 |
A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study |
Terminated |
NCT02594332 |
Phase 3 |
Mepolizumab;Placebo |
49 |
A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma |
Terminated |
NCT04049175 |
Phase 3 |
Treatment A;Treatment B;Treatment C;Treatment D |
50 |
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma |
Terminated |
NCT01290887 |
Phase 3 |
Reslizumab |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
hydroxyurea
imatinib
Imatinib mesylate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
|
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
|
Cochrane evidence based reviews: eosinophilia
|